Tryptophan Hydroxylase as Novel Target for the Treatment of Depressive Disorders

被引：60
作者：
Matthes, Susann [1 ]
Mosienko, Valentina [1 ]
Bashammakh, Saleh [1 ]
Alenina, Natalia [1 ]
Bader, Michael [1 ]
机构：
[1] Max Delbruck Ctr Mol Med, DE-13125 Berlin, Germany
来源：
PHARMACOLOGY | 2010年 / 85卷 / 02期
关键词：
Serotonin; Depression; Schizophrenia; Antidepressants; HUMAN TRYPTOPHAN-HYDROXYLASE-2 GENE; SEROTONIN-RELATED GENES; SINGLE NUCLEOTIDE POLYMORPHISM; BIPOLAR AFFECTIVE-DISORDER; OF-FUNCTION MUTATION; ISOFORM TPH2 GENE; SUICIDAL-BEHAVIOR; NO ASSOCIATION; MAJOR DEPRESSION; MOUSE MODEL;
D O I：
10.1159/000279322
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Serotonin (5-HT) is a monoamine implicated in a variety of physiological processes that functions either as a neurotransmitter or as a peripheral hormone. Pharmacological and genetic studies in humans and experimental animals have shown that 5-HT is important for the pathophysiology of depressive disorders. The 5-HT system is thus already a main target for the therapy of these diseases. The peripheral and cerebral biosynthesis of 5-HT is initiated by two distinct tryptophan hydroxylases: TPH1 and TPH2. This duality of the serotonergic system and the existence of a brain-specific TPH isoform provide a promising new target for pharmacological intervention with higher selectivity and specificity and, therefore, possibly with reduced side effects and increased efficiency. This paper summarizes the data which support TPH2 as novel drug target and discusses strategies for its pharmacological exploitation. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码：95 / 109
页数：15
相关论文
共 50 条
  • [41] A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders
    Guessoum, Selim Benjamin
    Le Strat, Yann
    Dubertret, Caroline
    Mallet, Jasmina
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2020, 99
  • [42] Impact of dissociation on treatment of depressive and anxiety spectrum disorders with and without personality disorders
    Prasko, Jan
    Grambal, Ales
    Kasalova, Petra
    Kamardova, Dana
    Ociskova, Marie
    Holubova, Michaela
    Vrbova, Kristyna
    Sigmundova, Zuzana
    Latalova, Klara
    Slepecky, Milos
    Zatkova, Marta
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 2659 - 2676
  • [43] The Tryptophan Hydroxylase 1 (TPH1) Gene, Schizophrenia Susceptibility, and Suicidal Behavior: A Multi-Centre Case-Control Study and Meta-Analysis
    Saetre, Peter
    Lundmark, Per
    Wang, August
    Hansen, Thomas
    Rasmussen, Henrik B.
    Djurovic, Srdjan
    Melle, Ingrid
    Andreassen, Ole A.
    Werge, Thomas
    Agartz, Ingrid
    Hall, Hakan
    Terenius, Lars
    Jonsson, Erik G.
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2010, 153B (02) : 387 - 396
  • [44] Depressive symptoms diagnosis and treatment of schizophrenia and schizophrenia spectrum disorders in Russian clinical practice
    Gurovich, I. Ya
    Shmukler, A. B.
    Storozhakova, Ya A.
    Kiryanova, E. M.
    Salnikova, L. I.
    Gazha, A. K.
    Maximova, N. E.
    Stepanova, O. N.
    Suchkov, Yu A.
    [J]. ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (11) : 28 - 33
  • [45] α2-containing GABAA receptors: A target for the development of novel treatment strategies for CNS disorders
    Engin, Elif
    Liu, Jing
    Rudolph, Uwe
    [J]. PHARMACOLOGY & THERAPEUTICS, 2012, 136 (02) : 142 - 152
  • [46] World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions
    Bauer, Michael
    Whybrow, Peter C.
    Angst, Jules
    Versiani, Marcio
    Moeller, Hans-Juergen
    [J]. REVISTA DE PSIQUIATRIA CLINICA, 2009, 36 : 58 - 76
  • [47] Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention
    Rossetti, Andrea Carlo
    Paladini, Maria Serena
    Riva, Marco Andrea
    Molteni, Raffaella
    [J]. PHARMACOLOGY & THERAPEUTICS, 2020, 210
  • [48] Stimulation of the β3-Adrenoceptor as a Novel Treatment Strategy for Anxiety and Depressive Disorders
    Jeanne Stemmelin
    Caroline Cohen
    Jean-Paul Terranova
    Matilde Lopez-Grancha
    Philippe Pichat
    Olivier Bergis
    Michel Decobert
    Vincent Santucci
    Dominique Françon
    Richard Alonso
    Stephen M Stahl
    Peter Keane
    Patrick Avenet
    Bernard Scatton
    Gérard le Fur
    Guy Griebel
    [J]. Neuropsychopharmacology, 2008, 33 : 574 - 587
  • [49] Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders
    Perez de la Mora, Miguel
    Borroto-Escuela, Dasiel O.
    Crespo-Ramirez, Minerva
    Rejon-Orantes, Jose del Carmen
    Palacios-Lagunas, Daniel Alejandro
    Martinez-Mata, Magda K.
    Sanchez-Luna, Daniela
    Tesoro-Cruz, Emiliano
    Fuxe, Kjell
    [J]. CELLS, 2022, 11 (11)
  • [50] Stimulation of the β3-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders
    Stemmelin, Jeanne
    Cohen, Caroline
    Terranova, Jean-Paul
    Lopez-Grancha, Matilde
    Pichat, Philippe
    Bergis, Olivier
    Decobert, Michel
    Santucci, Vincent
    Francon, Dominique
    Alonso, Richard
    Stahl, Stephen M.
    Keane, Peter
    Avenet, Patrick
    Scatton, Bernard
    le Fur, Gerard
    Griebel, Guy
    [J]. NEUROPSYCHOPHARMACOLOGY, 2008, 33 (03) : 574 - 587
12345